Latest Innovations from Cryoport Systems Enable Exceptional Patient Outcomes

In this in-depth conversation, Cryoport Systems showcases its expanding portfolio of logistics and bioservices designed to enable reliable, scalable, and compliant delivery of advanced therapies.

Aruna Mor (Chief Commercial Officer) introduces Cryoport’s holistic platform, which spans cryogenic logistics, bioservices, consulting, and global infrastructure—developed with a deep focus on risk mitigation and patient safety. Innovations such as the Cryoport Elite and HV3 shipping system, co-developed with clients like Sarepta, highlight the company’s collaborative approach to product design. These systems incorporate enhanced shock absorption, improved mobility, and compatibility with aircraft cargo constraints, reducing damage risk and streamlining patient access.

Michael Dybicz (Chief Product Development Officer) emphasizes how Cryoport works hand-in-hand with therapy developers throughout the product lifecycle—from clinical to commercial—using real-world user feedback to refine their systems. Their SafePak system, which protects cryogenically preserved blood cassettes, represents a new industry standard for safe transport.

Matthew Frazzetta (VP of Global Accounts, Bioservices) expands on Cryoport’s end-to-end capabilities, including ultra-cold storage, GMP-level packaging and labelling, QP services, and regulatory consulting. The team also provides lane risk assessments and trade compliance expertise, ensuring every shipment meets global standards and mitigates delays.

With rapid expansion of global facilities and continuous innovation in data, AI, and logistics tech, Cryoport is preparing for the next generation of therapies—including allogeneic and in vivo platforms—by ensuring the infrastructure is ready to scale with patient needs.